Description

Riletamotide is an immunological agent for active immunization[1].—–C76H132N22O21—-[1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 2, 2021.–524061-04-9–1690.00—-C[C@H](N)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer–10 mM in DMSO–Others—-Others–Peptides